Atorvastatin and Aβ(1-40): Not as Simple as Cholesterol Reduction in Brain and Relevance to Alzheimer Disease

Experimental Neurology

Volumn 228, Issue 1, 2011, Pages 15-18

  Butterfield, D Allan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXTRACELLULAR SUPEROXIDE DISMUTASE; GLUTAMATE TRANSPORTER; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROSTANE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SIMVASTATIN; TAU PROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALZHEIMER DISEASE; AMNESIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN CELL; CELL LOSS; CLINICAL TRIAL (TOPIC); ENZYME ACTIVATION; HUMAN; LEARNING; LIVER DISEASE; MUSCULOSKELETAL DISEASE; MYOPATHY; NERVE CELL DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NOTE; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CHOLESTEROL; HEPTANOIC ACIDS; HUMANS; PEPTIDE FRAGMENTS; PYRROLES;

EID: 79851511930     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.12.014     Document Type: Note

References (86)

1. Alberts A.W. Lovastatin and simvastatin - inhibitors of HMG CoA reductase and cholesterol biosynthesis. Cardiology 1990, 77:14-21.
2. Bliznakov E.G., Wilkins D.J. Biochemical and clinical consequences of inhibiting coenzyme Q(10) biosynthesis by lipid-lowering HMG-CoA reductase inhibitors (statins): a critical overview. Adv. Ther. 1998, 15:218-228.
3. Boyd-Kimball D., Sultana R., Poon H.F., Lynn B.C., Casamenti F., Pepeu G., Klein J.B., Butterfield D.A. Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease. Neuroscience 2005, 132:313-324.
4. Butterfield D.A., Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 2002, 32:1050-1060.
5. Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 2001, 7:548-554.
6. Butterfield D.A., Bader Lange M.L., Sultana R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim. Biophys. Acta 2010, 1801:924-929.
7. Butterfield D.A., Galvan V., Lange M.B., Tang H., Sowell R.A., Spilman P., Fombonne J., Gorostiza O., Zhang J., Sultana R., Bredesen D.E. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic. Biol. Med. 2010, 48:136-144.
8. Calabrese V., Sultana R., Scapagnini G., Guagliano E., Sapienza M., Bella R., Kanski J., Pennisi G., Mancuso C., Stella A.M., Butterfield D.A. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid. Redox Signal. 2006, 8:1975-1986.
9. Calabrese V., Mancuso C., Calvani M., Rizzarelli E., Butterfield D.A., Stella A.M. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat. Rev. Neurosci. 2007, 8:766-775.
10. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., Skene A.M. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004, 350:1495-1504.
11. Champagne D., Pearson D., Dea D., Rochford J., Poirier J. The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: Implications for Alzheimer's Disease. Neuroscience 2003, 121:99-110.
12. Chow S.C. Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases. Arch. Immunol. Ther. Exp. (Warsz) 2009, 57:243-251.
13. Clarke R.M., O'Connell F., Lyons A., Lynch M.A. The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-beta1-42 in the rat hippocampus in vivo. Neuropharmacology 2007, 52:136-145.
14. Cole S.L., Vassar R. Isoprenoids and Alzheimer's disease: a complex relationship. Neurobiol. Dis. 2006, 22:209-222.
15. Cordle A., Koenigsknecht-Talboo J., Wilkinson B., Limpert A., Landreth G. Mechanisms of statin-mediated inhibition of small G-protein function. J. Biol. Chem. 2005, 280:34202-34209.
16. Cramer C., Haan M.N., Galea S., Langa K.M., Kalbfleisch J.D. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008, 71:344-350.
17. Drake J., Link C.D., Butterfield D.A. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol. Aging 2003, 24:415-420.
18. Dufouil C., Richard F., Fievet N., Dartigues J.F., Ritchie K., Tzourio C., Amouyel P., Alperovitch A. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the three-city study. Neurology 2005, 64:1531-1538.
19. Farah S., Agazie Y., Ohan N., Ngsee J.K., Liu X.J. A rho-associated protein kinase, ROKalpha, binds insulin receptor substrate-1 and modulates insulin signaling. J. Biol. Chem. 1998, 273:4740-4746.
20. Fears R., Richards D.H., Ferres H. The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylgutaryl co-enzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks. Atherosclerosis 1980, 35:439-449.
21. Haag M.D., Hofman A., Koudstaal P.J., Stricker B.H., Breteler M.M. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. Neurosurg. Psychiatry 2009, 80:13-17.
22. Hajjar I., Schumpert J., Hirth V., Wieland D., Eleazer G.P. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J. Gerontol. A Biol. Sci. Med. Sci. 2002, 57:M414-M418.
23. Halliwell B., Gutteridge J. Free Radicals in Biology and Medicine 2007, Oxford University Press, Oxford. 4th ed.
24. Hartmann T. Cholesterol, A beta and Alzheimer's disease. Trends Neurosci. 2001, 24:S45-S48.
25. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet 2000, 356:1627-1631.
26. Joshi G., Aluise C.D., Cole M.P., Sultana R., Pierce W.M., Vore M., St Clair D.K., Butterfield D.A. Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: implications for oxidative stress-mediated chemobrain. Neuroscience 2010, 166:796-807.
27. Klopfleisch S., Merkler D., Schmitz M., Kloppner S., Schedensack M., Jeserich G., Althaus H.H., Bruck W. Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo. J. Neurosci. 2008, 28:13609-13614.
28. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., Sessa W.C., Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 2000, 6:1004-1010.
29. Kurinami H., Sato N., Shinohara M., Takeuchi D., Takeda S., Shimamura M., Ogihara T., Morishita R. Prevention of amyloid beta-induced memory impairment by fluvastatin, associated with the decrease in amyloid beta accumulation and oxidative stress in amyloid beta injection mouse model. Int. J. Mol. Med. 2008, 21:531-537.
30. Lambert J.C., Mann D.M., Harris J.M., Chartier-Harlin M.C., Cumming A., Coates J., Lemmon H., StClair D., Iwatsubo T., Lendon C. The-48C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer's disease and an increased Abeta load in brain. J. Med. Genet. 2001, 38:353-355.
31. Landmesser U., Bahlmann F., Mueller M., Spiekermann S., Kirchhoff N., Schulz S., Manes C., Fischer D., de Groot K., Fliser D., Fauler G., Marz W., Drexler H. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005, 111:2356-2363.
32. Langsjoen P.H., Langsjoen J.O., Langsjoen A.M., Lucas L.A. Treatment of statin adverse effects with supplemental coenzyme Q10 and statin drug discontinuation. Biofactors 2005, 25:147-152.
33. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., Wenger N.K. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 2005, 352:1425-1435.
34. Lauderback C.M., Hackett J.M., Huang F.F., Keller J.N., Szweda L.I., Markesbery W.R., Butterfield D.A. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J. Neurochem. 2001, 78:413-416.
35. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97:1129-1135.
36. Li G., Higdon R., Kukull W.A., Peskind E., Van Valen Moore K., Tsuang D., van Belle G., McCormick W., Bowen J.D., Teri L., Schellenberg G.D., Larson E.B. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004, 63:1624-1628.
37. Liao J.K., Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 2005, 45:89-118.
38. Lindberg C., Crisby M., Winblad B., Schultzberg M. Effects of statins on microglia. J. Neurosci. Res. 2005, 82:10-19.
39. Mancuso C., Scapagini G., Curro D., Giuffrida Stella A.M., De Marco C., Butterfield D.A., Calabrese V. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front. Biosci. 2007, 12:1107-1123.
40. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 1997, 23:134-147.
41. Masliah E., Alford M., DeTeresa R., Mallory M., Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann. Neurol. 1996, 40:759-766.
42. McTaggart S.J. Isoprenylated proteins. Cell. Mol. Life Sci. 2006, 63:255-267.
43. Miron V.E., Zehntner S.P., Kuhlmann T., Ludwin S.K., Owens T., Kennedy T.E., Bedell B.J., Antel J.P. Statin therapy inhibits remyelination in the central nervous system. Am. J. Pathol. 2009, 174:1880-1890.
44. Oda T., Wals P., Osterburg H.H., Johnson S.A., Pasinetti G.M., Morgan T.E., Rozovsky I., Stine W.B., Snyder S.W., Holzman T.F., Krafft G.A., Finch C.E. Clusterin (Apoj) alters the aggregation of amyloid beta-peptide (a-beta(1-42)) and forms slowly sedimenting a-beta complexes that cause oxidative stress. Exp. Neurol. 1995, 136:22-31.
45. Orr J.D. Statins in the spectrum of neurologic disease. Curr. Atheroscler. Rep. 2008, 10:11-18.
46. Owen, J.B., Sultana, R., Aluise, C.D., Erickson, M.A., Price, T.O., Bu, G., Banks, W.A., and Butterfield, D.A., 2010. Oxidative modification to LDL-related receptor protein 1 in hippocampus from subjects with Alzheimer disease: Implications for Abeta accumulation in AD brain. Free Radic. Biol. Med. 49, 1798-1803.
47. Pahan K., Sheikh F.G., Namboodiri A.M., Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. 1997, 100:2671-2679.
48. Pappolla M.A. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 2008, 71. 2020; author reply 2020-2021.
49. Parker R.A., Huang Q., Tesfamariam B. Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature. Atherosclerosis 2003, 169:19-29.
50. Perluigi M., Sultana R., Cenini G., Di Domenico F., Memo M., Pierce W.M., Coccia R., Butterfield D.A. Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics Clin. Appl. 2009, 3:682-693.
51. Petanceska S.S., DeRosa S., Olm V., Diaz N., Sharma A., Thomas-Bryant T., Duff K., Pappolla M., Refolo L.M. Statin therapy for Alzheimer's disease: will it work?. J. Mol. Neurosci. 2002, 19:155-161.
52. Petanceska S.S., DeRosa S., Sharma A., Diaz N., Duff K., Tint S.G., Refolo L.M., Pappolla M. Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol. J. Mol. Neurosci. 2003, 20:395-406.
53. Piermartiri, T.C., Figueiredo, C.P., Rial, D., Duarte, F.S., Bezerra, S.C., Mancini, G., de Bem, A.F., Prediger, R.D., and Tasca, C.I., 2010. Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-beta(1-40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage. Exp. Neurol. 226, 274-284.
54. Pratico D. The neurobiology of isoprostanes and Alzheimer's disease. Biochim. Biophys. Acta 2010, 1801:930-933.
55. Rea T.D., Breitner J.C., Psaty B.M., Fitzpatrick A.L., Lopez O.L., Newman A.B., Hazzard W.R., Zandi P.P., Burke G.L., Lyketsos C.G., Bernick C., Kuller L.H. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch. Neurol. 2005, 62:1047-1051.
56. Refolo L.M., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G.S., Sambamurti K., Duff K., Pappolla M.A. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 2000, 7:321-331.
57. Refolo L.M., Pappolla M.A., LaFrancois J., Malester B., Schmidt S.D., Thomas-Bryant T., Tint G.S., Wang R., Mercken M., Petanceska S.S., Duff K.E. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 2001, 8:890-899.
58. Riekse R.G., Li G., Petrie E.C., Leverenz J.B., Vavrek D., Vuletic S., Albers J.J., Montine T.J., Lee V.M., Lee M., Seubert P., Galasko D., Schellenberg G.D., Hazzard W.R., Peskind E.R. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J. Alzheimers Dis. 2006, 10:399-406.
59. Rockwood K. Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. Acta Neurol. Scand. Suppl. 2006, 185:71-77.
60. Rockwood K., Kirkland S., Hogan D.B., MacKnight C., Merry H., Verreault R., Wolfson C., McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 2002, 59:223-227.
61. Rodriguez E.G., Dodge H.H., Birzescu M.A., Stoehr G.P., Ganguli M. Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J. Am. Geriatr. Soc. 2002, 50:1852-1856.
62. Shie F.S., Jin L.W., Cook D.G., Leverenz J.B., LeBoeuf R.C. Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. NeuroReport 2002, 13:455-459.
63. Shinohara M., Sato N., Kurinami H., Takeuchi D., Takeda S., Shimamura M., Yamashita T., Uchiyama Y., Rakugi H., Morishita R. Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance. J. Biol. Chem. 2010, 285:22091-22102.
64. Simons M., Keller P., Strooper B.D., Beyreuther K., Dotti C.G., Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl Acad. Sci. USA 1998, 95:6460-6464.
65. Simons M., Schwarzler F., Lutjohann D., von Bergmann K., Beyreuther K., Dichgans J., Wormstall H., Hartmann T., Schulz J.B. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 2002, 52:346-350.
66. Smith M.A., Perry G., Pryor W.A. Causes and consequences of oxidative stress in Alzheimer's disease. Free Radic. Biol. Med. 2002, 32:1049.
67. Solomon A., Kareholt I., Ngandu T., Wolozin B., Macdonald S.W., Winblad B., Nissinen A., Tuomilehto J., Soininen H., Kivipelto M. Serum total cholesterol, statins and cognition in non-demented elderly. Neurobiol. Aging 2009, 30:1006-1009.
68. Sparks L. Statins and cognitive function. J. Neurol. Neurosurg. Psychiatry 2009, 80:1-2.
69. Sparks D.L., Sabbagh M.N., Connor D.J., Lopez J., Launer L.J., Browne P., Wasser D., Johnson-Traver S., Lochhead J., Ziolwolski C. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch. Neurol. 2005, 62:753-757.
70. Sparks D.L., Sabbagh M.N., Connor D.J., Lopez J., Launer L.J., Petanceska S., Browne P., Wassar D., Johnson-Traver S., Lochhead J., Ziolkowski C. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr. Alzheimer Res. 2005, 2:343-353.
71. Sparks D.L., Connor D.J., Sabbagh M.N., Petersen R.B., Lopez J., Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol. Scand. Suppl. 2006, 185:3-7.
72. Sparks D.L., Sabbagh M., Connor D., Soares H., Lopez J., Stankovic G., Johnson-Traver S., Ziolkowski C., Browne P. Statin therapy in Alzheimer's disease. Acta Neurol. Scand. Suppl. 2006, 185:78-86.
73. Subramaniam R., Roediger F., Jordan B., Mattson M.P., Keller J.N., Waeg G., Butterfield D.A. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J. Neurochem. 1997, 69:1161-1169.
74. Sultana R., Butterfield D.A. Oxidatively modified proteins in alzheimer's disease, mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol. 2009, 118:131-150.
75. Tamboli I.Y., Barth E., Christian L., Siepmann M., Singh S., Tolksdorf K., Heneka M.T., Luetjohann D., Wunderlich P., Walter J. Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated IDE secretion. J. Biol. Chem. 2010, 285:37405-37414.
76. Thelen K.M., Rentsch K.M., Gutteck U., Heverin M., Olin M., Andersson U., von Eckardstein A., Bjorkhem I., Lutjohann D. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J. Pharmacol. Exp. Ther. 2006, 316:1146-1152.
77. Todd P.A., Goa K.L. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1990, 40:583-607.
78. Tong X.K., Nicolakakis N., Fernandes P., Ongali B., Brouillette J., Quirion R., Hamel E. Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Neurobiol. Dis. 2009, 35:406-414.
79. Wallerath T., Poleo D., Li H., Forstermann U. Red wine increases the expression of human endothelial nitric oxide synthase: a mechanism that may contribute to its beneficial cardiovascular effects. J. Am. Coll. Cardiol. 2003, 41:471-478.
80. Walsh D.M., Hartley D.M., Kusumoto Y., Fezoui Y., Condron M.M., Lomakin A., Benedek G.B., Selkoe D.J., Teplow D.B. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 1999, 274:25945-25952.
81. Wang C.Y., Liu P.Y., Liao J.K. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol. Med. 2008, 14:37-44.
82. Whitfield J.F. The road to LOAD: late-onset Alzheimer's disease and a possible way to block it. Expert Opin. Ther. Targets 2007, 11:1257-1260.
83. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 2000, 57:1439-1443.
84. Wolozin B., Wang S.W., Li N.C., Lee A., Lee T.A., Kazis L.E. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007, 5:20.
85. Zamrini E., McGwin G., Roseman J.M. Association between statin use and Alzheimer's disease. Neuroepidemiology 2004, 23:94-98.
86. Zandi P.P., Sparks D.L., Khachaturian A.S., Tschanz J., Norton M., Steinberg M., Welsh-Bohmer K.A., Breitner J.C. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch. Gen. Psychiatry 2005, 62:217-224.